Mental illness is the health crisis of our time. We know that COVID-19 has had a compounding effect on this problem, and we know the current solutions are completely inadequate: 1 in 8 Australians take antidepressants which are nominally more effective than a placebo, and come with a number of serious side effects.
In the 1950s and 1960s a number of clinical trials into the therapeutic potential of psychedelics were conducted, and over 1,000 research papers were published. The results were hugely promising, but prohibitionist policies of the 1970s prematurely shuttered this line of inquiry. But we are now living through a renaissance.
Psylo is Australia’s first psychedelic biotech company, designing an entirely new class of psychedelic-inspired medications to treat mental illness. We believe that psychedelics hold incredible promise for treating some of society’s greatest mental illness challenges. Extensive R&D is needed to explore ways we might tap into the power these substances offer, and thereby discover solutions which are more accessible to a wider variety of sufferers.